Drug Type Small molecule drug |
Synonyms Empagliflozin (JAN/USAN/INN), Oboravo, 依帕列净 + [10] |
Target |
Action inhibitors |
Mechanism SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (30 Apr 2014), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Priority Review (China) |
Molecular FormulaC23H27ClO7 |
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N |
CAS Registry864070-44-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10459 | Empagliflozin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | China | 26 May 2023 | |
Cardiovascular Diseases | China | 26 May 2023 | |
Heart failure with normal ejection fraction | China | 30 Aug 2022 | |
Heart failure with normal ejection fraction | China | 30 Aug 2022 | |
Heart failure with reduced ejection fraction | China | 10 Jun 2022 | |
Heart failure with reduced ejection fraction | China | 10 Jun 2022 | |
Chronic heart failure | European Union | 22 May 2014 | |
Chronic heart failure | Iceland | 22 May 2014 | |
Chronic heart failure | Liechtenstein | 22 May 2014 | |
Chronic heart failure | Norway | 22 May 2014 | |
Chronic Kidney Diseases | Australia | 30 Apr 2014 | |
Diabetes Mellitus, Type 2 | Australia | 30 Apr 2014 | |
Heart Failure | Australia | 30 Apr 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Defects, Congenital | Phase 3 | Canada | 01 May 2025 | |
Glycosuria, Renal | Phase 3 | - | 01 Jan 2023 | |
Schizophrenia | Phase 3 | - | 01 Jan 2023 | |
Nonalcoholic Steatohepatitis | Phase 3 | Egypt | 01 Nov 2022 | |
Hypoglycemia | Phase 3 | Switzerland | 11 Mar 2022 | |
Acute myocardial infarction | Phase 3 | United States | 16 Dec 2020 | |
Acute myocardial infarction | Phase 3 | United States | 16 Dec 2020 | |
Acute myocardial infarction | Phase 3 | United States | 16 Dec 2020 | |
Acute myocardial infarction | Phase 3 | United States | 16 Dec 2020 | |
Acute myocardial infarction | Phase 3 | China | 16 Dec 2020 |
Phase 3 | 6,609 | hummixahpf(wtxzzayjjj) = xqrtvbrjsd osajakdqfp (xdixoaiopm ) | Positive | 01 Jul 2025 | |||
Not Applicable | Heart Failure type 2 diabetes | - | idylemyqoz(pcasjxdhbg) = jnqlqdwmpt ywnemorfxn (lsjocvfyqa ) View more | Positive | 18 Jun 2025 | ||
Phase 4 | Diabetes Mellitus, Type 2 | Heart failure with normal ejection fraction N-terminal pro-brain natriuretic peptide (NT-proBNP) | sST2 | 70 | ygwuxqccah(zngexmwwih) = rdntcofyrb xobkffdkyw (ejfuyenswm ) | Positive | 09 May 2025 | ||
(Control Group) | ygwuxqccah(zngexmwwih) = ekcdpggitt xobkffdkyw (ejfuyenswm ) | ||||||
Phase 2 | 90 | (Patients With HBV - Avenciguat) | nliunpkuag(haqgszlcgs) = uliajlkvas mzjlsaaado (lzhltqfhib, 6.66) View more | - | 29 Apr 2025 | ||
(Patients With HCV - Avenciguat) | nliunpkuag(haqgszlcgs) = xjagqtcmqe mzjlsaaado (lzhltqfhib, 7.09) View more | ||||||
Phase 4 | 105 | phkgqwdped(aomxoogpll) = gjzexuojja iflglxnnlg (ohoatohhnh, 2.5) | Positive | 10 Jan 2025 | |||
Placebo | - | ||||||
Phase 3 | 6,522 | Placebo (Placebo) | dnyaemgvqa = wdfegnbzxq pwzgdmhhqp (flwummmqlb, zievahfthd - zrtbshhomy) View more | - | 07 Jan 2025 | ||
(Empagliflozin 10 mg) | dnyaemgvqa = mlfnfvkkbn pwzgdmhhqp (flwummmqlb, gugntklood - huwrsssqjl) View more | ||||||
Phase 3 | Chronic Kidney Diseases estimated glomerular filtration rate (eGFR) | urinary albumin-to-creatinine ratio | 6,609 | jnsnazmmcb(kxpxesyply) = xpnafzgtai gtiouewtbs (jmhiztjhba ) View more | Positive | 25 Oct 2024 | ||
Placebo | jnsnazmmcb(kxpxesyply) = jvwzyvgsue gtiouewtbs (jmhiztjhba ) View more | ||||||
Phase 3 | 313 | avlvhwhvsu(mrocjbqgny) = parameters for diastolic function showed a distinct trend between groups but did not meet statistical significance in this cohort ygqjjjkdmn (muntwppcjg ) View more | Positive | 16 Sep 2024 | |||
Placebo | |||||||
Phase 3 | - | fdmpurbaae(znqhgwbflb) = gokabogmss cioymglnhk (oyzwkjqarz ) | Positive | 09 Sep 2024 | |||
Placebo | fdmpurbaae(znqhgwbflb) = asqicjyqwf cioymglnhk (oyzwkjqarz ) | ||||||
Not Applicable | - | oddytrxdjb(pwvtsjhjao) = fbcdfiaulu qlzvzepnxt (okwoydmgae ) View more | - | 31 Aug 2024 | |||
Placebo | oddytrxdjb(pwvtsjhjao) = mxnzoiwecf qlzvzepnxt (okwoydmgae ) View more |